A multivariate Cox analysis for the 200 CRC showed that the 6-GPS remained significantly associated with patients' RFS (HR=3.05; 95% CI: 1.66–5.60; P-value=3.36E-04; Table 3), after adjusting for tumor stage, gender, age, tumor location, mismatch repair status and gene mutation (BRAF and KRAS). This evidence concerns the gene KRAS and colorectal carcinoma.